HC Wainwright Reiterates Buy Rating for Alumis (NASDAQ:ALMS)

HC Wainwright reissued their buy rating on shares of Alumis (NASDAQ:ALMS) in a research report sent to investors on Monday morning,Benzinga reports. They currently have a $19.00 target price on the stock.

A number of other research analysts have also recently issued reports on ALMS. Oppenheimer initiated coverage on Alumis in a research note on Thursday, January 30th. They issued an “outperform” rating and a $32.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Alumis in a research report on Thursday, November 14th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Alumis currently has an average rating of “Buy” and an average price target of $26.57.

Alumis Price Performance

NASDAQ:ALMS opened at $4.72 on Monday. Alumis has a 1 year low of $4.36 and a 1 year high of $13.53. The stock has a 50-day moving average price of $6.52 and a two-hundred day moving average price of $9.26.

Institutional Trading of Alumis

Several institutional investors and hedge funds have recently bought and sold shares of ALMS. Towerview LLC raised its holdings in Alumis by 22.6% during the third quarter. Towerview LLC now owns 380,000 shares of the company’s stock worth $4,058,000 after acquiring an additional 70,000 shares in the last quarter. Charles Schwab Investment Management Inc. bought a new stake in Alumis in the third quarter valued at approximately $1,160,000. BNP Paribas Financial Markets bought a new stake in Alumis in the third quarter valued at approximately $27,000. MetLife Investment Management LLC bought a new stake in Alumis in the third quarter valued at approximately $89,000. Finally, Maven Securities LTD raised its stake in Alumis by 100.0% in the third quarter. Maven Securities LTD now owns 50,000 shares of the company’s stock valued at $534,000 after buying an additional 25,000 shares during the period.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.